CHINA

Medical Group Endorses Antimalarial Drugs For Critical COVID-19 Patients Despite Experimental Basis

FDA Commissioner Stephen Hahn said that, while the antimalarials have not yet been formally approved, access could be expanded so that authorities could gather more data
After the Trump administration's controversial stance on using anti-malarial drugs to treat critically ill COVID-19 patients, medical groups endorsed its usage and released guidelines, although, these guidelines were based on experimental anecdotes. Meanwhile, President Trump made a call to the Indian Prime Minister to request for hydroxychloroquine stocks, which the country manufacture in large amounts.
More news

Pages

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.